Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study

Thomas O Crawford, Sergey V Paushkin, Dione T Kobayashi, Suzanne J Forrest, Cynthia L Joyce, Richard S Finkel, Petra Kaufmann, Kathryn J Swoboda, Danilo Tiziano, Rosa Lomastro, Rebecca H Li, Felicia L Trachtenberg, Thomas Plasterer, Karen S Chen, Pilot Study of Biomarkers for Spinal Muscular Atrophy Trial Group, Margaret Bell, David Jacoby, Robert McBurney, Wendy Chung, Louise Simard, Mustafa Sahin, Thomas O Crawford, Sergey V Paushkin, Dione T Kobayashi, Suzanne J Forrest, Cynthia L Joyce, Richard S Finkel, Petra Kaufmann, Kathryn J Swoboda, Danilo Tiziano, Rosa Lomastro, Rebecca H Li, Felicia L Trachtenberg, Thomas Plasterer, Karen S Chen, Pilot Study of Biomarkers for Spinal Muscular Atrophy Trial Group, Margaret Bell, David Jacoby, Robert McBurney, Wendy Chung, Louise Simard, Mustafa Sahin

Abstract

Background: The universal presence of a gene (SMN2) nearly identical to the mutated SMN1 gene responsible for Spinal Muscular Atrophy (SMA) has proved an enticing incentive to therapeutics development. Early disappointments from putative SMN-enhancing agent clinical trials have increased interest in improving the assessment of SMN expression in blood as an early "biomarker" of treatment effect.

Methods: A cross-sectional, single visit, multi-center design assessed SMN transcript and protein in 108 SMA and 22 age and gender-matched healthy control subjects, while motor function was assessed by the Modified Hammersmith Functional Motor Scale (MHFMS). Enrollment selectively targeted a broad range of SMA subjects that would permit maximum power to distinguish the relative influence of SMN2 copy number, SMA type, present motor function, and age.

Results: SMN2 copy number and levels of full-length SMN2 transcripts correlated with SMA type, and like SMN protein levels, were lower in SMA subjects compared to controls. No measure of SMN expression correlated strongly with MHFMS. A key finding is that SMN2 copy number, levels of transcript and protein showed no correlation with each other.

Conclusion: This is a prospective study that uses the most advanced techniques of SMN transcript and protein measurement in a large selectively-recruited cohort of individuals with SMA. There is a relationship between measures of SMN expression in blood and SMA type, but not a strong correlation to motor function as measured by the MHFMS. Low SMN transcript and protein levels in the SMA subjects relative to controls suggest that these measures of SMN in accessible tissues may be amenable to an "early look" for target engagement in clinical trials of putative SMN-enhancing agents. Full length SMN transcript abundance may provide insight into the molecular mechanism of phenotypic variation as a function of SMN2 copy number.

Trial registry: Clinicaltrials.gov NCT00756821.

Conflict of interest statement

Competing Interests: See below for the Full List of Competing Interests.

Figures

Figure 1. Modified Hammersmith Functional Motor Scale…
Figure 1. Modified Hammersmith Functional Motor Scale versus age by SMA cohort.
Scores for the MHFMS were well-distributed by age across the enrollment cohorts. It should be noted that not all control individuals achieved a score of 40 on the scale, while all Type I SMA subjects were assigned scores of zero in the assessment.
Figure 2. SMN2 copy numbers in SMA…
Figure 2. SMN2 copy numbers in SMA and Control subjects.
SMN2 copy number is lower in Controls than it is in SMA subjects, in whom copy number is related to type.
Figure 3. SMN2 copy number relationship to…
Figure 3. SMN2 copy number relationship to age, and by SMA Type or Control.
Subjects with each SMA type are broadly distributed across the age range, with the exception of type I SMA for whom there is some bias to younger age. As a consequence, SMN2 copy numbers are also broadly distributed. Values have been plotted with a small y-axis offset to avoid overlap of values.
Figure 4. SMN transcript concentrations in SMA…
Figure 4. SMN transcript concentrations in SMA and Control subjects.
A,C: SMN2-FL, SMN-FL and Total SMN transcripts generally increase with SMA Type. SMN-FL (A) is a sum of SMN1-FL (present only in healthy controls) and SMN2-FL. B: SMN-Δ7 expression levels are lower in Type I patients compared to other SMA Types but they are similar to that of Controls. D: Ratios of SMN2-FL to SMN- Δ7 differ between SMA Types and Controls, however differences between SMA Types are absent with the exception of Type II versus Type III patients. E: GAPDH transcript levels are elevated in SMA Type I and Controls relative to Type II and III patients.
Figure 5. SMN protein levels in SMA…
Figure 5. SMN protein levels in SMA and Control Subjects.
While SMN protein levels are lower in SMA relative to Control subjects, protein levels by SMA type are not statistically different from each other.

References

    1. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358–368.
    1. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20–26.
    1. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997;60:1411–1422.
    1. Lefebvre S, Burlet P, Viollet L, Bertrandy S, Huber C, et al. A novel association of the SMN protein with two major non-ribosomal nucleolar proteins and its implication in spinal muscular atrophy. Hum Mol Genet. 2002;11:1017–1027.
    1. Owen N, Doe CL, Mellor J, Davies KE. Characterization of the Schizosaccharomyces pombe orthologue of the human survival motor neuron (SMN) protein. Hum Mol Genet. 2000;9:675–684.
    1. Paushkin S, Charroux B, Abel L, Perkinson RA, Pellizzoni L, et al. The survival motor neuron protein of Schizosacharomyces pombe. Conservation of survival motor neuron interaction domains in divergent organisms. J Biol Chem. 2000;275:23841–23846.
    1. Schrank B, Gotz R, Gunnersen JM, Ure JM, Toyka KV, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A. 1997;94:9920–9925.
    1. Wang J, Dreyfuss G. Characterization of functional domains of the SMN protein in vivo. J Biol Chem. 2001;276:45387–45393.
    1. Oskoui M, Kaufmann P. Spinal muscular atrophy. Neurotherapeutics. 2008;5:499–506.
    1. Mattis VB, Rai R, Wang J, Chang CW, Coady T, et al. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet. 2006;120:589–601.
    1. Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med. 2009;1:5ra12.
    1. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72ra18.
    1. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest. 2010;120:1253–1264.
    1. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28:271–274.
    1. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010;2:35ra42.
    1. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011;20:681–693.
    1. Mercuri E, Bertini E, Messina S, Solari A, D’Amico A, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology. 2007;68:51–55.
    1. Chen TH, Chang JG, Yang YH, Mai HH, Liang WC, et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology. 2010;75:2190–2197.
    1. Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010;5:e12140.
    1. Crawford TO. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord. 2004;14:456–460.
    1. Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, et al. Observational Study of Spinal Muscular Atrophy Type 2 and 3: Functional Outcomes Over 1 Year. Arch Neurol. 2011;0:20103731–8.
    1. Munsat TL, Davies KE. International SMA consortium meeting. (26–28 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2:423–428.
    1. Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, et al. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology. 2006;66:1067–1073.
    1. Kolb SJ, Gubitz AK, Olszewski RF, Jr, Ottinger E, Sumner CJ, et al. A novel cell immunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol. 2006;6:6.
    1. Vezain M, Saugier-Veber P, Melki J, Toutain A, Bieth E, et al. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Eur J Hum Genet. 2007;15:1054–1062.
    1. Tiziano FD, Pinto AM, Fiori S, Lomastro R, Messina S, et al. SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet. 2010;18:52–58.
    1. Simard LR, Belanger MC, Morissette S, Wride M, Prior TW, et al. Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology. 2007;68:451–456.
    1. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord. 2006;16:417–426.
    1. Oskoui M, Levy G, Garland CJ, Gray JM, O’Hagen J, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931–1936.
    1. Gomez-Curet I, Robinson KG, Funanage VL, Crawford TO, Scavina M, et al. Robust quantification of the SMN gene copy number by real-time TaqMan PCR. Neurogenetics. 2007;8:271–278.
    1. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
    1. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12:1015–1023.
    1. Hendrickson BC, Donohoe C, Akmaev VR, Sugarman EA, Labrousse P, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet. 2009;46:641–644.
    1. Burghes AH. When is a deletion not a deletion? When it is converted. Am J Hum Genet. 1997;61:9–15.
    1. Wirth B, Schmidt T, Hahnen E, Rudnik-Schoneborn S, Krawczak M, et al. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet. 1997;61:1102–1111.
    1. Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999;64:1340–1356.
    1. Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85:408–413.
    1. Chang HC, Dimlich DN, Yokokura T, Mukherjee A, Kankel MW, et al. Modeling spinal muscular atrophy in Drosophila. PLoS One. 2008;3:e3209.
    1. Dimitriadi M, Sleigh JN, Walker A, Chang HC, Sen A, et al. Conserved Genes Act as Modifiers of Invertebrate SMN Loss of Function Defects. PLoS Genet. 2010;6:e1001172.
    1. Sen A, Yokokura T, Kankel MW, Dimlich DN, Manent J, et al. Modeling spinal muscular atrophy in Drosophila links Smn to FGF signaling. J Cell Biol. 2011;192:481–495.
    1. Oprea GE, Krober S, McWhorter ML, Rossoll W, Muller S, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008;320:524–527.
    1. Martins de Araujo M, Bonnal S, Hastings ML, Krainer AR, Valcarcel J. Differential 3' splice site recognition of SMN1 and SMN2 transcripts by U2AF and U2 snRNP. Rna. 2009;15:515–523.
    1. Singh NN, Seo J, Ottesen EW, Shishimorova M, Bhattacharya D, et al. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol Cell Biol. 2011;31:935–954.
    1. Pedrotti S, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, et al. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. Embo J. 2010;29:1235–1247.
    1. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008;82:834–848.
    1. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26:1333–1346.
    1. Singh NN, Androphy EJ, Singh RN. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. Rna. 2004;10:1291–1305.
    1. Singh NN, Singh RN, Androphy EJ. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res. 2007;35:371–389.
    1. Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol. 2009;6:341–350.
    1. Chen HH, Chang JG, Lu RM, Peng TY, Tarn WY. The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Mol Cell Biol. 2008;28:6929–6938.
    1. Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet. 2003;34:460–463.
    1. Kashima T, Rao N, Manley JL. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc Natl Acad Sci U S A. 2007;104:3426–3431.
    1. Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002;30:377–384.
    1. Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. 2006;78:63–77.
    1. Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, et al. Candidate Proteins, Metabolites and Transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study. PLoS ONE. 2012;7:e35462. doi: .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel